Ajanta Pharma promoters just borrowed against another 2.2% of the company.
Gabs Investments pledged 27.7 lakh shares for a new loan, pushing the group's total pledged stake to 13.9% of equity.
— 5 earlier stories on Ajanta Pharma Ltd. →What's new
- Promoter entity Gabs Investments pledged 27.7 lakh shares (2.22% of equity) on June 2 for a new loan.
- The total promoter encumbered stake rose from 11.7% to 13.9% in one transaction.
- CTL Trusteeship Limited is the lender. The loan's size and terms are undisclosed.
Why this matters
A 2.2 percentage point jump in a single day is the kind of move that flags a new need for cash. At 13.9%, the promoter group's stake is now meaningfully encumbered. The lack of details on the loan's purpose leaves a question mark over the motivation.
What we're watching
- Whether the 13.9% encumbered stake continues to climb toward the 15% level.
- Any further disclosures on the loan's purpose, size, or maturity.
- Promoter buying or selling activity in the open market.
The full read
Ajanta Pharma's promoter group just borrowed against another 2.2% of the company. Gabs Investments, a promoter entity, pledged 27.7 lakh shares on June 2, lifting the total encumbered stake to 13.9% of equity. CTL Trusteeship is the lender. No terms were disclosed. The move itself is routine. The size is not. A 2.2 percentage point jump in a single transaction pushes the group's pledged stake into territory that demands attention. At 13.9%, the promoter's control over the company is increasingly tied to the lender's patience. If the stock falls, the lender can sell. What changes from here is whether this is a one-off or the start of a trend.
Questions answered
- What did Gabs Investments do, and what is CTL Trusteeship?
- Gabs Investments borrowed against 27.7 lakh shares, or 2.22% of Ajanta Pharma's equity, using CTL Trusteeship as the lender. The filing gives no information on the loan's amount or terms.
- How significant is the 2.2 percentage point increase?
- It is a material single-day move, lifting the total pledged stake from 11.7% to 13.9%. A jump of this size typically draws scrutiny because it shows a clear new need for funds against the stock.
- Does the filing reveal why the promoter needed the loan?
- No. The disclosure states the pledge was for a new loan but provides no purpose, interest rate, or maturity date. The reason for the borrowing remains opaque.
- What is the direct risk to other shareholders?
- A pledge gives the lender the right to sell the shares if the stock price falls. At 13.9% of equity, that potential selling pressure is a material overhang on the stock.
Ajanta Pharma Ltd.
Latest quarter · Mar 2026
Strength & growth
Story so far
All notes on AJANTPHARM →- 9 Jun 2026 · 10:22 AM IST Ajanta Pharma promoters just borrowed against another 2.2% of the company.
- 25d ago Ajanta Pharma promoters pledge 13.5% equity to back ₹3,873 cr outside debt
- 25d ago Ajanta Pharma promoter pledges 10.06 lakh shares; encumbered stake at 10.83%
- 39d ago Ajanta Pharma promoter trust releases 23.26 lakh pledged shares
- 43d ago Ajanta Pharma promoter pledges additional 0.89% stake to RBL Bank